TELA Bio (TELA)
Market Price (11/16/2026): $0.8356 | Market Cap: $37.8 MilSector: Health Care | Industry: Life Sciences Tools & Services
TELA Bio (TELA)
Market Price (11/16/2026): $0.8356Market Cap: $37.8 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Aging Population & Chronic Disease. Themes include Surgical Biomaterials, and Geriatric Care. | Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -160% | Penny stockMkt Price is 0.8 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -34 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -43% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 72% Weak revenue growthRev Chg QQuarterly Revenue Change % is -8.4% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -94% Key risksTELA key risks include [1] its consistent history of operating losses and need to secure additional capital, Show more. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Aging Population & Chronic Disease. Themes include Surgical Biomaterials, and Geriatric Care. |
| Weak multi-year price returns2Y Excs Rtn is -100%, 3Y Excs Rtn is -160% |
| Penny stockMkt Price is 0.8 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -34 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -43% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 72% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -8.4% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -94% |
| Key risksTELA key risks include [1] its consistent history of operating losses and need to secure additional capital, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Nov 12: down 8.7% in one day (S&P 500 down 0.4%)
The stock moved down without company news. The S&P 500 also declined that day.
Down 44.7% from its Sep 22 high to Nov 5, up 5.1% since (S&P 500 down 5.2%)
The stock experienced a decline without specific company news driving the overall run. This included big drops on September 23, October 2, and October 30, during a period when the S&P 500 also moved down.
Nov 11: up 17.7% the day after its Nov 10 earnings report (S&P 500 up 1.3%)
The stock gained after the third quarter 2026 financial results were released. The company reported a 21% reduced sequential operating loss, and Zacks Investment Research stated it beat revenue estimates.
Nov 12: down 8.7% in one day (S&P 500 down 0.4%)
The stock moved down without company news. The S&P 500 also declined that day.
Down 44.7% from its Sep 22 high to Nov 5, up 5.1% since (S&P 500 down 5.2%)
The stock experienced a decline without specific company news driving the overall run. This included big drops on September 23, October 2, and October 30, during a period when the S&P 500 also moved down.
Nov 11: up 17.7% the day after its Nov 10 earnings report (S&P 500 up 1.3%)
The stock gained after the third quarter 2026 financial results were released. The company reported a 21% reduced sequential operating loss, and Zacks Investment Research stated it beat revenue estimates.
Show less
Stock Movement Drivers
Fundamental Drivers
The 12.4% change in TELA stock from 7/31/2026 to 11/15/2026 was primarily driven by a 17.0% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 11152026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.73 | 0.82 | 12.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 81 | 78 | -3.3% |
| P/S Multiple | 0.5 | 0.6 | 17.0% |
| Shares Outstanding (Mil) | 57 | 58 | -0.7% |
| Cumulative Contribution | 12.4% |
Market Drivers
7/31/2026 to 11/15/2026| Return | Correlation | |
|---|---|---|
| TELA | 12.4% | |
| Market (SPY) | 1.2% | 39.0% |
| Sector (XLV) | 16.6% | 16.0% |
Fundamental Drivers
The -6.3% change in TELA stock from 4/30/2026 to 11/15/2026 was primarily driven by a -10.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 4302026 | 11152026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.87 | 0.82 | -6.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 80 | 78 | -2.6% |
| P/S Multiple | 0.6 | 0.6 | 7.3% |
| Shares Outstanding (Mil) | 52 | 58 | -10.3% |
| Cumulative Contribution | -6.3% |
Market Drivers
4/30/2026 to 11/15/2026| Return | Correlation | |
|---|---|---|
| TELA | -6.3% | |
| Market (SPY) | 5.5% | 22.2% |
| Sector (XLV) | 30.4% | 12.9% |
Fundamental Drivers
The -33.3% change in TELA stock from 10/31/2025 to 11/15/2026 was primarily driven by a -21.4% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 11152026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.23 | 0.82 | -33.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 75 | 78 | 3.8% |
| P/S Multiple | 0.7 | 0.6 | -18.3% |
| Shares Outstanding (Mil) | 45 | 58 | -21.4% |
| Cumulative Contribution | -33.3% |
Market Drivers
10/31/2025 to 11/15/2026| Return | Correlation | |
|---|---|---|
| TELA | -33.3% | |
| Market (SPY) | 11.8% | 19.2% |
| Sector (XLV) | 33.1% | 9.1% |
Fundamental Drivers
The -86.0% change in TELA stock from 10/31/2023 to 11/15/2026 was primarily driven by a -78.1% change in the company's P/S Multiple.| (LTM values as of) | 10312023 | 11152026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.84 | 0.82 | -86.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 49 | 78 | 59.0% |
| P/S Multiple | 2.8 | 0.6 | -78.1% |
| Shares Outstanding (Mil) | 23 | 58 | -59.7% |
| Cumulative Contribution | -86.0% |
Market Drivers
10/31/2023 to 11/15/2026| Return | Correlation | |
|---|---|---|
| TELA | -86.0% | |
| Market (SPY) | 87.0% | 18.0% |
| Sector (XLV) | 59.4% | 14.2% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| TELA Return | -15% | -10% | -42% | -54% | -61% | -30% | -95% |
| Peers Return | 4% | -15% | -8% | -24% | 55% | -12% | -14% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 103% |
Monthly Win Rates [3] | |||||||
| TELA Win Rate | 42% | 58% | 33% | 33% | 33% | 45% | |
| Peers Win Rate | 56% | 53% | 47% | 42% | 56% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 45% | |
Max Drawdowns [4] | |||||||
| TELA Max Drawdown | -32% | -60% | -63% | -70% | -71% | -53% | |
| Peers Max Drawdown | -33% | -44% | -52% | -42% | -36% | -45% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, COCH, FRNM.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)
How Low Can It Go
| Event | TELA | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -70.0% | -33.7% |
| % Gain to Breakeven | 233.0% | 50.9% |
| Time to Breakeven | 89 days | 140 days |
In The Past
TELA Bio's stock fell -70.0% during the 2020 COVID-19 Crash. Such a loss loss requires a 233.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | TELA | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -70.0% | -33.7% |
| % Gain to Breakeven | 233.0% | 50.9% |
| Time to Breakeven | 89 days | 140 days |
In The Past
TELA Bio's stock fell -70.0% during the 2020 COVID-19 Crash. Such a loss loss requires a 233.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About TELA Bio (TELA)
TELA Bio, Inc. (TELA) is a commercial-stage medical technology company dedicated to developing and commercializing soft-tissue reconstruction solutions. The company's core focus is on optimizing clinical outcomes for patients by providing advanced products that prioritize the preservation and restoration of a patient's natural anatomy.
TELA Bio's main product offering is its proprietary OviTex Reinforced Tissue Matrix. This portfolio includes OviTex products specifically designed for use in hernia repair and abdominal wall reconstruction. Additionally, the company offers OviTex PRS Reinforced Tissue Matrix, which addresses unmet needs in plastic and reconstructive surgery, and OviTex for Laparoscopic and Robotic Procedures, a specialized matrix for minimally invasive hernia surgical repairs. These innovative products are sterile reinforced tissue matrices derived from ovine rumen, incorporating polypropylene fiber for enhanced performance.
The company markets its products to surgical professionals and healthcare facilities primarily within the United States. TELA Bio utilizes a single direct sales force to reach its target customers who perform soft-tissue reconstruction procedures, including various types of hernia repairs, abdominal wall reconstructions, and plastic and reconstructive surgeries.
AI Analysis | Feedback
Here are 1-2 brief analogies for TELA Bio (TELA):
- Medtronic for soft-tissue repair.
- Integra LifeSciences for reconstructive soft-tissue matrices.
AI Analysis | Feedback
- OviTex Reinforced Tissue Matrix (OviTex): A portfolio of products used for hernia repair and abdominal wall reconstruction.
- OviTex PRS Reinforced Tissue Matrix: Products specifically designed to address unmet needs in plastic and reconstructive surgery.
- OviTex for Laparoscopic and Robotic Procedures: A sterile reinforced tissue matrix used in laparoscopic and robotic-assisted hernia surgical repairs.
AI Analysis | Feedback
TELA Bio (TELA) is a medical technology company that provides soft-tissue reconstruction solutions, including reinforced tissue matrices for hernia repair, abdominal wall reconstruction, and plastic/reconstructive surgery. The company sells its products through a direct sales force, primarily in the United States.
Given the nature of its products as medical devices used in surgical procedures, TELA Bio's customers are not individual patients, but rather healthcare providers and institutions. While the company does not typically disclose specific major "customer companies" (such as publicly traded hospital chains) in its public filings, its customer base can be categorized as follows:
- Hospitals: This includes general hospitals, academic medical centers, and specialized surgical hospitals that perform procedures such as hernia repair, abdominal wall reconstruction, and various plastic and reconstructive surgeries.
- Ambulatory Surgical Centers (ASCs): These outpatient facilities are increasingly performing a range of surgical procedures, including many types of hernia repairs, and are key purchasers of medical devices.
- Surgeons and Healthcare Professionals: While typically operating within hospitals or ASCs, individual surgeons are often the primary decision-makers for the adoption and use of specific medical devices. TELA Bio's direct sales force targets these professionals to drive product adoption.
AI Analysis | Feedback
- Collagen Matrix, Inc.
AI Analysis | Feedback
Antony Koblish, Co-founder & Chief Executive Officer
Antony Koblish is a medical device entrepreneur with 25 years of experience in healthcare. He co-founded TELA Bio in 2012. Prior to founding TELA Bio, Mr. Koblish was President and Chief Executive Officer of Orthovita, Inc., a publicly traded orthobiologics and biosurgery medical device company. During his tenure as CEO of Orthovita from 2002 to 2011, he grew the company's valuation from $30 million to a $316 million exit sale to Stryker Corporation in 2011. He is also a co-founder and serves as Chairman of the Board of Onkos Surgical, Inc., a surgical oncology company. Additionally, Mr. Koblish is an operating partner with 1315 Capital, a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare services companies.
Roberto Cuca, Chief Operating Officer & Chief Financial Officer
Roberto Cuca joined TELA Bio in September 2021, bringing over 25 years of experience in operational and finance positions within the healthcare industry. Most recently, Mr. Cuca served as Chief Financial Officer of OraSure Technologies, a point-of-care testing and sample collection technologies company. Before that, he was Senior Vice President and Chief Financial Officer of Trevana, Inc., a clinical-stage biopharmaceutical company. Mr. Cuca also held various leadership positions within the finance organization of Endo Health Solutions Inc., a pharmaceutical company, including Treasurer and Senior Vice President, Finance, where he was responsible for capital raises, cash management, mergers, acquisitions, licensing transactions, tax planning, compliance, and risk management.
Jeffrey Blizard, President
Jeffrey Blizard was appointed President of TELA Bio in June 2025. He previously served on TELA Bio's Board of Directors for a year prior to his appointment. Mr. Blizard possesses significant industry experience and a proven leadership track record, having led successful teams at Abiomed and other prominent medtech companies.
Paul Talmo, Chief Technology Officer
Paul Talmo serves as the Chief Technology Officer for TELA Bio.
Greg Firestone, Chief Business Officer
Greg Firestone holds the position of Chief Business Officer at TELA Bio.
```AI Analysis | Feedback
Here are the key risks to TELA Bio's business:
- Inability to Achieve or Sustain Profitability and Need for Additional Capital: TELA Bio consistently reports significant net losses and has an accumulated deficit, indicating it is not yet profitable. The company has a substantial cash burn rate due to ongoing operating expenses and investment in commercial expansion, leading to a high dependence on external financing to fund its operations. Future funding may be expensive, dilutive to existing shareholders, and not available on acceptable terms, which could severely limit the company's ability to grow.
- Heavy Reliance on a Limited Product Portfolio and Intense Competition: The majority of TELA Bio's revenue is generated from its OviTex family of reinforced tissue matrices, making the company highly dependent on the commercial success and market acceptance of these products. Any adverse events, such as regulatory setbacks, new competitive offerings, or negative clinical data related to OviTex, could significantly impact the company's financial health. TELA Bio operates in a competitive environment, facing challenges like competitive sales representative poaching, which has disrupted sales operations and could hinder market share growth. Additionally, declining average selling prices for some hernia products may put pressure on profitability.
- Regulatory and Supply Chain Risks: As a medical technology company, TELA Bio must comply with extensive government regulations both in the U.S. and internationally. Delays or failures in obtaining necessary regulatory clearances or approvals for new products or modifications could harm the business. Furthermore, the specialized manufacturing process for its core OviTex product relies on a single-source supplier, creating a single point of failure in the supply chain. Macroeconomic conditions and broader supply chain disruptions also pose risks that could negatively impact operations.
AI Analysis | Feedback
AI Analysis | Feedback
TELA Bio, Inc. operates in the soft-tissue reconstruction market, focusing on hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company estimates its total addressable markets for its main products in the United States as follows:
- For OviTex products used in hernia repair and abdominal wall reconstruction, the annual U.S. total addressable market opportunity is approximately $1.8 billion.
- For OviTex PRS products addressing the needs in plastic and reconstructive surgery, the annual U.S. current addressable market opportunity is approximately $800 million.
The combined U.S. market opportunity for TELA Bio's products, encompassing hernia and abdominal wall reconstruction and plastic reconstructive surgery, is estimated to be $2.6 billion.
AI Analysis | Feedback
TELA Bio (symbol: TELA) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Expansion of Product Portfolio and Adoption of Recently Launched Products: TELA Bio anticipates significant revenue growth from the continued adoption and increased penetration of its OviTex and OviTex PRS products. Key contributions are expected from recently launched innovations such as OviTex IHR (Inguinal Hernia Repair) Reinforced Tissue Matrix, designed for laparoscopic and robotic-assisted inguinal hernia repair, and larger sizes of OviTex PRS Reinforced Tissue Matrix, which address evolving needs in plastic and reconstructive surgery and simplify complex cases. The strategic partnership for LIQUIFIX fixation technology also contributes to this growth by offering complementary solutions.
- International Market Expansion: TELA Bio is actively pursuing growth in international markets, particularly in Europe. The company has reported significant momentum and expanding commercial presence in Europe, including the launch of OviTex Inguinal Reinforced Tissue Matrix in June 2025. This expansion into new geographies is expected to be a notable driver of future revenue.
- Increased Penetration within Existing Accounts and New Customer Acquisition in Robotic Procedures: The company's revenue growth is driven by increasing unit sales through deeper penetration within its existing customer accounts and the addition of new customers. A specific focus is on capturing market share in high-volume, minimally invasive, and robotic procedures, with products like OviTex IHR being designed with robotic compatibility in mind.
- Growth and Efficiency of the Direct Sales Force: TELA Bio is investing in and expanding its single direct sales force. The company has achieved its budgeted commercial headcount and aims for further expansion, alongside initiatives to improve sales rep training and overall operational efficiency. This enhanced commercial organization is expected to drive increased product adoption and sales productivity.
AI Analysis | Feedback
Share Issuance
- In October 2024, TELA Bio completed a public offering of common stock and pre-funded warrants, generating gross proceeds of $46 million.
- In April 2023, the company priced a public offering of common stock, resulting in gross proceeds of $45.125 million.
- In August 2022, TELA Bio completed an underwritten public offering of common stock for gross proceeds of $36.8 million.
Inbound Investments
- In November 2025, TELA Bio secured a senior secured term loan facility with Perceptive Credit Holdings V, LP, for up to $70.0 million, with an initial funding of $60.0 million.
- In May 2022, the company entered into a new credit facility with MidCap Financial, providing access to a total credit of up to $50 million, including an initial tranche of $40 million.
Outbound Investments
- TELA Bio recognized a $7.6 million gain on the sale of its NIVIS product line in fiscal year 2024.
Capital Expenditures
- Capital expenditures were approximately $357,000 in fiscal year 2024.
- Capital expenditures were approximately $302,000 in fiscal year 2023.
- In the third quarter of 2025, capital expenditures totaled $211,000.
Peer Outperformance in Life Sciences Tools & Services
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| TELA | TELA Bio | 14.3% | -1.1x | -17.9% | -82.7% | -93.4% | — |
| MEDP | Medpace | 16.8% | 35.3x | 10.8% | 132.3% | 198.9% | +292pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 10.3% | 56.1% | 108.0% | CAH 517% · MCK 409% · COR 206% |
| Health Care Services | 20 | 30.9% | 20.9% | 12.5% | RDNT 145% · HIMS 141% · DGX 95% |
| Managed Health Care | 8 | 72.3% | -2.6% | 2.7% | OSCR 155% · HQY 54% · HUM 8% |
| Health Care Facilities | 26 | 18.0% | 25.0% | -6.7% | THC 257% · NHC 227% · EHC 196% |
| Health Care Equipment | 50 | 7.8% | 11.1% | -15.2% | GKOS 401% · UFPT 346% · TMDX 255% |
| Pharmaceuticals | 60 | -15.0% | 7.7% | -39.5% | LQDA 1081% · KNSA 639% · XERS 572% |
| Health Care Supplies | 11 | 26.2% | 6.1% | -39.8% | LNTH 241% · HAE 112% · MMSI 27% |
| Life Sciences Tools & Services ← | 109 | -15.3% | -17.9% | -74.4% | AXGN 378% · MEDP 199% · NTRA 175% |
| Biotechnology | 365 | -26.3% | -32.0% | -81.4% | ELVN 1259% · TRVI 1141% · DNTH 1129% |
| Health Care Technology | 22 | -20.8% | -57.2% | -82.3% | VEEV -4% · DOCS -53% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| TELA Bio Earnings Notes | 12/16/2025 | |
| How Low Can TELA Bio Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.91 |
| Mkt Cap | 0.8 |
| Rev LTM | 227 |
| Op Inc LTM | -24 |
| FCF LTM | -10 |
| FCF 3Y Avg | -22 |
| CFO LTM | 3 |
| CFO 3Y Avg | -1 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.1% |
| Rev Chg 3Y Avg | 13.8% |
| Rev Chg Q | 9.5% |
| QoQ Delta Rev Chg LTM | 2.3% |
| Op Inc Chg LTM | 13.5% |
| Op Inc Chg 3Y Avg | 5.5% |
| Op Mgn LTM | -3.0% |
| Op Mgn 3Y Avg | -12.4% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 1.5% |
| CFO/Rev 3Y Avg | -0.6% |
| FCF/Rev LTM | -1.2% |
| FCF/Rev 3Y Avg | -12.1% |
Price Behavior
| Market Price | $0.82 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 11/08/2019 | |
| Distance from 52W High | -41.8% | |
| 50 Days | 200 Days | |
| DMA Price | $1.03 | $0.85 |
| DMA Trend | up | down |
| Distance from DMA | -20.6% | -3.5% |
| 3M | 1YR | |
| Volatility | 94.1% | 96.1% |
| Downside Capture | 70.42 | 139.12 |
| Upside Capture | 271.90 | 99.98 |
| Correlation (S&P 500) | 35.5% | 18.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.97 | 2.32 | 2.96 | 1.12 | 1.08 | 0.86 |
| Up Beta | -13.78 | 3.43 | 7.29 | 3.00 | 1.12 | 0.83 |
| Down Beta | 3.48 | 4.73 | 4.35 | 2.40 | 1.51 | 1.51 |
| Up Capture | 58% | 194% | 178% | -8% | 45% | 1% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 6 | 19 | 31 | 60 | 115 | 321 |
| Down Capture | 485% | 92% | 115% | 49% | 118% | 100% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 15 | 23 | 32 | 65 | 128 | 400 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TELA | |
|---|---|---|---|---|
| TELA | -28.2% | 96.1% | 0.08 | - |
| Sector ETF (XLV) | 25.8% | 16.8% | 1.18 | 9.8% |
| Equity (SPY) | 11.6% | 13.7% | 0.54 | 18.9% |
| Gold (GLD) | -7.9% | 28.9% | -0.29 | -0.5% |
| Commodities (DBC) | 33.8% | 21.3% | 1.26 | -2.0% |
| Real Estate (VNQ) | 10.7% | 14.2% | 0.47 | 5.6% |
| Bitcoin (BTCUSD) | -33.0% | 43.7% | -0.79 | 14.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TELA | |
|---|---|---|---|---|
| TELA | -42.4% | 71.3% | -0.47 | - |
| Sector ETF (XLV) | 9.1% | 15.4% | 0.39 | 16.0% |
| Equity (SPY) | 11.5% | 17.3% | 0.49 | 20.7% |
| Gold (GLD) | 15.9% | 19.2% | 0.66 | 1.7% |
| Commodities (DBC) | 7.8% | 19.6% | 0.28 | 2.8% |
| Real Estate (VNQ) | 1.3% | 18.9% | -0.04 | 15.4% |
| Bitcoin (BTCUSD) | 2.2% | 51.6% | 0.23 | 10.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with TELA | |
|---|---|---|---|---|
| TELA | -24.2% | 72.4% | -0.22 | - |
| Sector ETF (XLV) | 13.0% | 16.8% | 0.64 | 20.9% |
| Equity (SPY) | 15.5% | 18.0% | 0.73 | 26.4% |
| Gold (GLD) | 11.1% | 16.6% | 0.54 | 4.5% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | 10.6% |
| Real Estate (VNQ) | 6.3% | 20.7% | 0.26 | 23.5% |
| Bitcoin (BTCUSD) | 58.4% | 66.2% | 0.98 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/13/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2026 | 17.7% | ||
| 8/10/2026 | -15.1% | -30.1% | -2.0% |
| 5/12/2026 | -5.9% | -15.7% | -10.6% |
| 3/24/2026 | -9.4% | -18.6% | -18.3% |
| 11/13/2025 | -10.0% | -4.5% | 6.3% |
| 8/11/2025 | -14.0% | -8.6% | -15.6% |
| 5/8/2025 | 9.0% | -1.1% | 87.8% |
| 3/20/2025 | -37.2% | -41.5% | -62.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 10 | 10 |
| # Negative | 17 | 15 | 15 |
| Median Positive | 7.5% | 6.2% | 8.9% |
| Median Negative | -7.3% | -6.4% | -11.7% |
| Max Positive | 24.6% | 28.7% | 87.8% |
| Max Negative | -37.2% | -41.5% | -62.0% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/10/2026 | 17.7% | ||
| 8/10/2026 | -15.1% | -30.1% | -2.0% |
| 5/12/2026 | -5.9% | -15.7% | -10.6% |
| 3/24/2026 | -9.4% | -18.6% | -18.3% |
| 11/13/2025 | -10.0% | -4.5% | 6.3% |
| 8/11/2025 | -14.0% | -8.6% | -15.6% |
| 5/8/2025 | 9.0% | -1.1% | 87.8% |
| 3/20/2025 | -37.2% | -41.5% | -62.0% |
| 11/7/2024 | 2.8% | 1.7% | 1.3% |
| 8/12/2024 | -22.9% | -23.4% | -34.2% |
| 5/9/2024 | 16.8% | 28.7% | 12.6% |
| 3/21/2024 | 7.1% | 6.0% | -14.6% |
| 11/9/2023 | -19.4% | -17.1% | -7.7% |
| 8/9/2023 | -3.3% | -0.8% | -1.3% |
| 5/11/2023 | -3.7% | -3.7% | 10.7% |
| 3/21/2023 | -5.9% | 3.3% | -11.7% |
| 11/9/2022 | 24.6% | 23.1% | 58.5% |
| 8/10/2022 | -5.1% | -2.6% | 2.3% |
| 5/10/2022 | -7.3% | -5.7% | -32.5% |
| 3/21/2022 | -6.8% | -6.4% | -22.1% |
| 11/10/2021 | -0.2% | 1.2% | 1.9% |
| 8/11/2021 | 7.5% | 8.9% | -6.2% |
| 5/13/2021 | 6.2% | 13.3% | 11.2% |
| 3/24/2021 | -8.3% | 6.4% | -3.6% |
| 1/14/2021 | 2.2% | 5.7% | 7.1% |
| 11/12/2020 | -0.5% | -0.2% | -0.7% |
| SUMMARY STATS | |||
| # Positive | 9 | 10 | 10 |
| # Negative | 17 | 15 | 15 |
| Median Positive | 7.5% | 6.2% | 8.9% |
| Median Negative | -7.3% | -6.4% | -11.7% |
| Max Positive | 24.6% | 28.7% | 87.8% |
| Max Negative | -37.2% | -41.5% | -62.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/10/2026 | 10-Q |
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/25/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/10/2026 | 10-Q |
| 06/30/2026 | 08/11/2026 | 10-Q |
| 03/31/2026 | 05/13/2026 | 10-Q |
| 12/31/2025 | 03/25/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/11/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/21/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 03/22/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/23/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/23/2022 | 10-K |
| 09/30/2021 | 11/12/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/14/2021 | 10-Q |
| 12/31/2020 | 03/25/2021 | 10-K |
| 09/30/2020 | 11/12/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/15/2020 | 10-Q |
| 12/31/2019 | 03/30/2020 | 10-K |
Insider Activity
Updated 10/19/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capper, Joseph H | Direct | Buy | 9182026 | 1.22 | 25,000 | 30,530 | 219,605 | Form | |
| 2 | Capper, Joseph H | Direct | Buy | 9182026 | 1.17 | 50,000 | 58,265 | 180,420 | Form | |
| 3 | Capper, Joseph H | Direct | Buy | 9162026 | 1.06 | 50,000 | 52,940 | 110,991 | Form | |
| 4 | Capper, Joseph H | Direct | Buy | 9162026 | 1.02 | 25,000 | 25,502 | 55,929 | Form | |
| 5 | Getz, Heather C | Chief Executive Officer | Direct | Buy | 8192026 | 0.66 | 12,500 | 8,311 | 354,059 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capper, Joseph H | Direct | Buy | 9182026 | 1.22 | 25,000 | 30,530 | 219,605 | Form | |
| 2 | Capper, Joseph H | Direct | Buy | 9182026 | 1.17 | 50,000 | 58,265 | 180,420 | Form | |
| 3 | Capper, Joseph H | Direct | Buy | 9162026 | 1.06 | 50,000 | 52,940 | 110,991 | Form | |
| 4 | Capper, Joseph H | Direct | Buy | 9162026 | 1.02 | 25,000 | 25,502 | 55,929 | Form | |
| 5 | Getz, Heather C | Chief Executive Officer | Direct | Buy | 8192026 | 0.66 | 12,500 | 8,311 | 354,059 | Form |
| 6 | Getz, Heather C | Chief Executive Officer | Direct | Buy | 8172026 | 0.70 | 15,000 | 10,467 | 362,856 | Form |
| 7 | Ew, Healthcare Partners Fund 2, LP | Direct | Buy | 11172025 | 1.11 | 3,604,000 | 4,000,440 | 8,563,327 | Form |
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
